About daratumumab
CD38-targeted monoclonal antibody
Used for
- Treats multiple myeloma, alone or with other cancer medicines.
- Treats light-chain amyloidosis with other medicines in eligible adults.
Usual adult dose
Usually 16 mg/kg by intravenous infusion weekly at first, then less often; schedule depends on treatment combination and stage.
Common side effects
- Infusion-related reactions, including breathing problems or fever
- Fatigue, nausea, diarrhea, or constipation
- Low blood cell counts and increased infection risk
- Muscle or joint pain
Important warnings
- Infusion reactions can be severe, especially during the first infusion.
- Can cause serious infections and low blood counts.
- Interferes with blood-bank compatibility testing; tell the blood bank before transfusions.
- Can affect certain tests used to monitor multiple myeloma.
Pregnancy
May harm an unborn baby. Effective contraception is recommended during treatment and for three months after the last dose.
Breastfeeding
Breastfeeding is not recommended during treatment and for three months after the last dose.
Interactions
- May interfere with blood typing and crossmatching; notify transfusion services.
- May affect laboratory tests that measure myeloma proteins.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.